354 related articles for article (PubMed ID: 19473660)
1. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis.
Moreno JA; Muñoz-García B; Martín-Ventura JL; Madrigal-Matute J; Orbe J; Páramo JA; Ortega L; Egido J; Blanco-Colio LM
Atherosclerosis; 2009 Nov; 207(1):103-10. PubMed ID: 19473660
[TBL] [Abstract][Full Text] [Related]
2. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.
Moreno JA; Dejouvencel T; Labreuche J; Smadja DM; Dussiot M; Martin-Ventura JL; Egido J; Gaussem P; Emmerich J; Michel JB; Blanco-Colio LM; Meilhac O
Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1253-62. PubMed ID: 20299688
[TBL] [Abstract][Full Text] [Related]
3. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
Valdivielso JM; Coll B; Martín-Ventura JL; Moreno JA; Egido J; Fernández E; Blanco-Colio LM
J Nephrol; 2013; 26(6):1105-13. PubMed ID: 23475462
[TBL] [Abstract][Full Text] [Related]
4. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease.
Urbonaviciene G; Martin-Ventura JL; Lindholt JS; Urbonavicius S; Moreno JA; Egido J; Blanco-Colio LM
Atherosclerosis; 2011 Dec; 219(2):892-9. PubMed ID: 21962403
[TBL] [Abstract][Full Text] [Related]
5. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis.
Kowal-Bielecka O; Bielecki M; Guiducci S; Trzcinska-Butkiewicz B; Michalska-Jakubus M; Matucci-Cerinic M; Brzosko M; Krasowska D; Chyczewski L; Kowal K
Arthritis Res Ther; 2013; 15(3):R69. PubMed ID: 23800379
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension.
Jasiewicz M; Kowal K; Kowal-Bielecka O; Knapp M; Skiepko R; Bodzenta-Lukaszyk A; Sobkowicz B; Musial WJ; Kaminski KA
Cytokine; 2014 Mar; 66(1):40-5. PubMed ID: 24548423
[TBL] [Abstract][Full Text] [Related]
7. Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure.
Ptaszynska-Kopczynska K; Marcinkiewicz-Siemion M; Lisowska A; Waszkiewicz E; Witkowski M; Jasiewicz M; Miklasz P; Jakim P; Galar B; Musial WJ; Kaminski KA
Cytokine; 2016 Apr; 80():7-12. PubMed ID: 26916171
[TBL] [Abstract][Full Text] [Related]
8. CD163+ macrophages are associated with a vulnerable plaque phenotype in human carotid plaques.
Bengtsson E; Hultman K; Edsfeldt A; Persson A; Nitulescu M; Nilsson J; Gonçalves I; Björkbacka H
Sci Rep; 2020 Sep; 10(1):14362. PubMed ID: 32873809
[TBL] [Abstract][Full Text] [Related]
9. The association of high sCD163/sTWEAK ratio with cardiovascular disease in hemodialysis patients.
Rusu CC; Racasan S; Kacso IM; Ghervan L; Moldovan D; Potra A; Patiu IM; Bondor C; Caprioara MG
Int Urol Nephrol; 2015 Dec; 47(12):2023-30. PubMed ID: 26433887
[TBL] [Abstract][Full Text] [Related]
10. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications.
Bover LC; Cardó-Vila M; Kuniyasu A; Sun J; Rangel R; Takeya M; Aggarwal BB; Arap W; Pasqualini R
J Immunol; 2007 Jun; 178(12):8183-94. PubMed ID: 17548657
[TBL] [Abstract][Full Text] [Related]
11. Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection.
Dirajlal-Fargo S; Sattar A; Kulkarni M; Funderburg N; McComsey GA
HIV Clin Trials; 2017 Jul; 18(4):156-163. PubMed ID: 28828963
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study.
Llauradó G; González-Clemente JM; Maymó-Masip E; Subías D; Vendrell J; Chacón MR
PLoS One; 2012; 7(8):e43919. PubMed ID: 22937125
[TBL] [Abstract][Full Text] [Related]
13. Role of the tumour necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) axis in autoimmune thyroid disease.
Peng S; Yu X; Zhao X; Wang X; Sun X; Han C; Shan Z; Li C; Teng W
Clin Endocrinol (Oxf); 2017 Dec; 87(6):783-790. PubMed ID: 28636775
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis.
Moreno JA; Ortega-Gómez A; Delbosc S; Beaufort N; Sorbets E; Louedec L; Esposito-Farèse M; Tubach F; Nicoletti A; Steg PG; Michel JB; Feldman L; Meilhac O
Eur Heart J; 2012 Jan; 33(2):252-63. PubMed ID: 21606088
[TBL] [Abstract][Full Text] [Related]
15. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
[TBL] [Abstract][Full Text] [Related]
16. Soluble macrophage-derived CD163: a homogenous ectodomain protein with a dissociable haptoglobin-hemoglobin binding.
Møller HJ; Nielsen MJ; Maniecki MB; Madsen M; Moestrup SK
Immunobiology; 2010 May; 215(5):406-12. PubMed ID: 19581020
[TBL] [Abstract][Full Text] [Related]
17. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
[TBL] [Abstract][Full Text] [Related]
19. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis.
Aristoteli LP; Møller HJ; Bailey B; Moestrup SK; Kritharides L
Atherosclerosis; 2006 Feb; 184(2):342-7. PubMed ID: 15979079
[TBL] [Abstract][Full Text] [Related]
20. Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases.
Fernández-Laso V; Sastre C; Valdivielso JM; Fernández E; Martín-Ventura JL; Egido J; Blanco-Colio LM
Atherosclerosis; 2015 Apr; 239(2):358-63. PubMed ID: 25681674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
